These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 34033528)

  • 41. Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2.
    Firouzabadi N; Ghasemiyeh P; Moradishooli F; Mohammadi-Samani S
    Int Immunopharmacol; 2023 Apr; 117():109968. PubMed ID: 37012880
    [TBL] [Abstract][Full Text] [Related]  

  • 42. COVID-19 vaccine hesitancy - reasons and solutions to achieve a successful global vaccination campaign to tackle the ongoing pandemic.
    Dhama K; Sharun K; Tiwari R; Dhawan M; Emran TB; Rabaan AA; Alhumaid S
    Hum Vaccin Immunother; 2021 Oct; 17(10):3495-3499. PubMed ID: 34191680
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO).
    McLeod C; Ramsay J; Flanagan KL; Plebanski M; Marshall H; Dymock M; Marsh J; Estcourt MJ; Wadia U; Williams PCM; Tjiam MC; Blyth C; Subbarao K; Nicholson S; Faust S; Thornton RB; Mckenzie A; Snelling TL; Richmond P
    Trials; 2023 Mar; 24(1):202. PubMed ID: 36934272
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Innovation-driven trend shaping COVID-19 vaccine development in China.
    Zhang Y; Zhao Y; Liang H; Xu Y; Zhou C; Yao Y; Wang H; Yang X
    Front Med; 2023 Dec; 17(6):1096-1116. PubMed ID: 38102402
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 46. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
    Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA
    Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
    Al-Kassmy J; Pedersen J; Kobinger G
    Viruses; 2020 Aug; 12(8):. PubMed ID: 32784685
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact of immuno-aging on SARS-CoV-2 vaccine development.
    Connors J; Bell MR; Marcy J; Kutzler M; Haddad EK
    Geroscience; 2021 Feb; 43(1):31-51. PubMed ID: 33569701
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges.
    Cooper DM; Afghani B; Byington CL; Cunningham CK; Golub S; Lu KD; Radom-Aizik S; Ross LF; Singh J; Smoyer WE; Lucas CT; Tunney J; Zaldivar F; Ulloa ER
    Pediatr Res; 2021 Nov; 90(5):966-970. PubMed ID: 33627824
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness of mRNA, protein subunit vaccine and viral vectors vaccines against SARS-CoV-2 in people over 18 years old: a systematic review.
    Sandoval C; Guerrero D; Muñoz J; Godoy K; Souza-Mello V; Farías J
    Expert Rev Vaccines; 2023; 22(1):35-53. PubMed ID: 36484136
    [TBL] [Abstract][Full Text] [Related]  

  • 51. VITT, COVID-19 and the Expert Haematology Panel: The story of how the UK responded to emerging cases of vaccine-induced immune thrombocytopenia and thrombosis during the vaccination programme.
    Chevassut T; Hunt BJ; Pavord S
    Clin Med (Lond); 2021 Nov; 21(6):e600-e602. PubMed ID: 34645700
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vaccine and vaccination as a part of human life: In view of COVID-19.
    K B M; Nayar SA; P V M
    Biotechnol J; 2022 Jan; 17(1):e2100188. PubMed ID: 34665927
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice.
    Chaparian RR; Harding AT; Hamele CE; Riebe K; Karlsson A; Sempowski GD; Heaton NS; Heaton BE
    J Virol; 2022 Aug; 96(15):e0068922. PubMed ID: 35862698
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mapping the technological landscape of SARS, MERS, and SARS-CoV-2 vaccines.
    Nascimento Júnior JAC; Santos AM; Cavalcante RCM; Quintans-Júnior LJ; Walker CIB; Borges LP; Frank LA; Serafini MR
    Drug Dev Ind Pharm; 2021 Apr; 47(4):673-684. PubMed ID: 33826439
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.
    Joe CCD; Jiang J; Linke T; Li Y; Fedosyuk S; Gupta G; Berg A; Segireddy RR; Mainwaring D; Joshi A; Cashen P; Rees B; Chopra N; Nestola P; Humphreys J; Davies S; Smith N; Bruce S; Verbart D; Bormans D; Knevelman C; Woodyer M; Davies L; Cooper L; Kapanidou M; Bleckwenn N; Pappas D; Lambe T; Smith DC; Green CM; Venkat R; Ritchie AJ; Gilbert SC; Turner R; Douglas AD
    Biotechnol Bioeng; 2022 Jan; 119(1):48-58. PubMed ID: 34585736
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants.
    Li T; Luo KQ
    Int J Biol Sci; 2022; 18(12):4642-4647. PubMed ID: 35874950
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?
    Joshi G; Borah P; Thakur S; Sharma P; Mayank ; Poduri R
    Hum Vaccin Immunother; 2021 Dec; 17(12):4714-4740. PubMed ID: 34856868
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaccine development for emerging infectious diseases.
    Excler JL; Saville M; Berkley S; Kim JH
    Nat Med; 2021 Apr; 27(4):591-600. PubMed ID: 33846611
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena.
    Chavda VP; Bezbaruah R; Athalye M; Parikh PK; Chhipa AS; Patel S; Apostolopoulos V
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.